| 7.41 1.23 (19.9%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.78 |
1-year : | 10.25 |
| Resists | First : | 7.51 |
Second : | 8.78 |
| Pivot price | 6.06 |
|||
| Supports | First : | 6.23 |
Second : | 5.44 |
| MAs | MA(5) : | 6.32 |
MA(20) : | 6.09 |
| MA(100) : | 5.83 |
MA(250) : | 6.04 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 81.5 |
D(3) : | 67 |
| RSI | RSI(14): 70.4 |
|||
| 52-week | High : | 7.94 | Low : | 3.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EOLS ] has closed Bollinger Bands are 24.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.52 - 7.55 | 7.55 - 7.57 |
| Low: | 6.47 - 6.5 | 6.5 - 6.53 |
| Close: | 7.36 - 7.4 | 7.4 - 7.45 |
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Wed, 05 Aug 2026
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2 - Yahoo! Finance Canada
Wed, 05 Aug 2026
Is Evolus Inc (EOLS) Undervalued After Q2 Earnings Beat? EPS: -0 - GuruFocus
Wed, 05 Aug 2026
symbol__ Stock Quote Price and Forecast - CNN
Wed, 05 Aug 2026
Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses - Quiver Quantitative
Wed, 05 Aug 2026
Evolus (Nasdaq: EOLS) posts higher sales and manages sizable debt load - Stock Titan
Wed, 05 Aug 2026
Evolus (NASDAQ: EOLS) lifts 2026 guidance after Q2 revenue hits $84.1 million - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 66 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 14.6 (%) |
| Held by Institutions | 70.3 (%) |
| Shares Short | 5,910 (K) |
| Shares Short P.Month | 5,900 (K) |
| EPS | -0.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.44 |
| Profit Margin | -14.4 % |
| Operating Margin | -9.4 % |
| Return on Assets (ttm) | -9.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 6.6 % |
| Gross Profit (p.s.) | 3.02 |
| Sales Per Share | 4.58 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -11.23 |
| PEG Ratio | 0 |
| Price to Book value | -16.85 |
| Price to Sales | 1.61 |
| Price to Cash Flow | -13.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|